Publication:
Use of Biphasic Insulin Aspart 30 in Type 2 Diabetes Treatment: Expert Panel Recommendations

dc.contributor.authorYAVUZ, DİLEK
dc.contributor.authorsAkalin, Sema; Aydin, Hasan; Balci, Mustafa Kemal; Comlekci, Abdurrahman; Dinccag, Nevin; Erbas, Tomris; Ersoz, Halil Onder; Yavuz, Dllek Gogas; Gullu, Sevim; Sahin, Ibrahim; Siva, Zeynep Oscar; Unluhizarci, Kursad
dc.date.accessioned2022-03-10T11:38:41Z
dc.date.accessioned2026-01-11T15:34:09Z
dc.date.available2022-03-10T11:38:41Z
dc.date.issued2018
dc.description.abstractThe goals of Type 2 diabetes treatment are to eliminate the hyperglycemia resulting from insulin insufficiency and/or insulin resistance, delay beta cell damage/depletion, and prevent other metabolic co-morbidities and complications. In the current treatment algorithms, lifestyle changes (medical nutrition therapy, physical exercise) and oral anti-diabetics are followed by insulin therapy, which is considered a replacement therapy for Type 2 diabetes. Pre-mixed insulin preparations, which are an option for patients with poor blood glucose level control under oral anti-diabetics treatment, have been developed to meet both basal and prandial insulin needs by simulating the physiological changes in insulin levels. The consensus on the necessity of individualizing insulin therapy requires physicians to have a detailed knowledge of the various uses of insulin. Therefore, this comprehensive consensus statement has been prepared by a panel of expert endocrinologists from different regions of Turkey to help physicians use biphasic insulin aspart 30 in suitable patients at the right time. In this statement, expert panel opinions on (a) Recommendations for the appropriate initiation, titration, and intensification of insulin treatment, and (b) The treatment algorithms in initiation, titration, and intensification of biphasic insulin aspart 30 treatment and special conditions specific to changing treatment regimen are presented.
dc.identifier.doi10.25179/tjem.2017-57420
dc.identifier.issn1301-2193
dc.identifier.urihttps://hdl.handle.net/11424/219776
dc.identifier.wosWOS:000443340300007
dc.language.isoeng
dc.publisherGALENOS YAYINCILIK
dc.relation.ispartofTURKISH JOURNAL OF ENDOCRINOLOGY AND METABOLISM
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBiphasic insulin aspart 30
dc.subjectinsulin intensification
dc.subjectpremixed insulin
dc.subjectinsulin analog
dc.subjectPOSTPRANDIAL PLASMA-GLUCOSE
dc.subjectPANCREATIC-CANCER
dc.subjectGLYCEMIC CONTROL
dc.subjectCLINICAL ENDOCRINOLOGISTS
dc.subjectCARDIOVASCULAR EVENTS
dc.subjectAMERICAN ASSOCIATION
dc.subjectPREMIXED FORMULATION
dc.subjectINDEPENDENT RISK
dc.subjectHUMALOG MIX25
dc.subjectBLOOD-GLUCOSE
dc.titleUse of Biphasic Insulin Aspart 30 in Type 2 Diabetes Treatment: Expert Panel Recommendations
dc.typereview
dspace.entity.typePublication
oaire.citation.endPage197
oaire.citation.issue3
oaire.citation.startPage183
oaire.citation.titleTURKISH JOURNAL OF ENDOCRINOLOGY AND METABOLISM
oaire.citation.volume22

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
file.pdf
Size:
603.76 KB
Format:
Adobe Portable Document Format